ItsGas you're quoting something from 5 years ago for MS and the company has been unable to find anybody interested in taking it for almost 10 years since Teva handed back post the Phase II trial.
The asthma paragraph you quoted is from almost 15 years ago.
They've also been unable to find anybody interested in 1103 for Acromegaly since Cortendo handed it back and after completing the Phase II trial almost 5 years ago.
Until it proves differently it's all about DMD and yes it is 1 trick pony until then.
ANP “not a one trick Pony”, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.001(1.32%) |
Mkt cap ! $68.51M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.6¢ | $18.83K | 247.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13033 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 191003 | 2 |
View Market Depth
| Last trade - 13.53pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.001 ( 3.80 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.6¢ | 7.6¢ | 54789 | ||
| Last updated 11.44am 21/05/2024 ? | |||||
| PER (ASX) Chart |